comparemela.com

Ultimovacs Asa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ultimovacs Announces Webcast to Elaborate on the Results

NON-REGULATORY PRESS RELEASE Oslo, October 25, 2023: Ultimovacs ASA (

Company onEuronext oslo stock exchangePrincipal investigatorOslo stock exchange ultiUltimovacs asa

Ultimovacs Announces NIPU Results Presented at ESMO 2023:

UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall.

Bristol myers squibbBristol meyers squibbInternational agency for research on cancer globocanOslo university hospitalEuronext oslo stock exchangeHalle universityPrincipal investigatorSaturday octoberCarlos de sousaOrphan drug designationInternational agencyHuman leukocyte antigenOslo stock exchange ultiUltimovacs asa

Ultimovacs Announces that the Results from UV1 Phase II

The results from the NIPU study will be presented by the Principal Investigator as an oral presentation at the ESMO Congress 2023 in Madrid, Spain, 20-24.

Bristol myers squibbProfessor at oslo university hospitalOslo university hospitalPrincipal investigatorOslo stock exchange ultiUltimovacs asa

Ultimovacs ASA Reports First Quarter 2023 Financial Results

Oslo, May 10, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces.

Hans vassgPhase ii clinical development programEuropean patent officeNorwegian securities tradingOslo stock exchange ultiUltimovacs asa

Ultimovacs ASA: Share capital increase related to exercise

Oslo, 16 November 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital, related to the.

Hans vassgNorwegian register of business enterprisesNorwegian registerBusiness enterprisesOslo stock exchange ultiUltimovacs asa

vimarsana © 2020. All Rights Reserved.